Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of atezolizumab versus gemcitabine plus platinum in previously untreated metastatic squamous non-small cell lung cancer
2014-003106-33Phase 3Completed
- Sponsor
- Roche
- Start
- May 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, gemcitabine, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started May 2015; status: completed.
02
Drugs
atezolizumabgemcitabinecisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2014-003106-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003106-33.